Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified miRNAs within the Dlk1-Gtl2 region on chromosome 18 as potential epigenetic regulators of lamb fur traits, with possible implications for the PI3K-AKT signaling pathway.

BTNL2 helps protect hair follicles from immune attacks.

This paper reviews the use of interferons, particularly alfa interferon, in treating cutaneous T-cell lymphoma, noting its substantial efficacy both alone and in combination therapies with predictable, generally well-tolerated side effects.

This study investigated dermal fibroblasts in mouse skin using single-cell RNA sequencing and identified signaling pathways that influence adipogenesis, finding that IL-1-NF-κB promotes, while WNT-β-catenin inhibits, the adipogenic potential of these cells, with implications for wound healing and scar formation.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

In this study, daily treatment with ritlecitinib for up to 24 months led to significant reductions in high-severity alopecia areata SALT scores among patients aged ≥12 years, including those with severe forms such as alopecia totalis and universalis.

This systematic review reported an association between specific interleukin gene polymorphisms (IL-17A, IL-18, IL17RA, and IL16) and alopecia areata, suggesting further genetic studies are needed to confirm the interleukins' role in the disorder's progression.

This study found that local injections of interleukin-4 and neutralizing anti-interferon-γ antibody effectively treated alopecia in a mouse model, suggesting potential therapeutic pathways for human alopecia areata.

In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

This study found that the IL-33/ST2 axis may protect against skin carcinogenesis by promoting cross-talk between epithelial cells and regulatory T cells to minimize mutations and contain tissue damage.

IL-13 protein is much higher in the skin of atopic dermatitis patients than in healthy skin.

In this case report, a 40-year-old woman with systemic lupus erythematosus developed Type B Insulin Resistance Syndrome, characterized by severe hyperglycemia despite high insulin doses, requiring immunosuppressive therapy to manage refractory symptoms.

An 8-year-old girl developed a rare skin condition in a linear pattern on one side of her body after a lung infection, which improved with treatment.

In laboratory tests and mouse models, this study found that the novel IPC analog SIG-1451 may offer potent anti-inflammatory effects for treating allergic skin inflammation, potentially outperforming some current therapies in specific inflammatory phases.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

This study found that 87% of patients with stage IIA and IIB melanoma treated with low-dose alpha-interferon reported cutaneous side effects, with the most common being hair loss.

This review examines complex regional pain syndrome (CRPS I) mechanisms, including immune dysregulation and psychological factors, but reports no new clinical results; the authors highlight potential diagnostic refinements.

The study found that IPI-926 was well tolerated up to 160 mg once daily for 28-day cycles and showed activity as a single-agent treatment in Hedgehog pathway inhibitor-naïve patients with basal cell carcinoma.

This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.

In this study, researchers found that overexpression of LncRNA RP11-818O24.3 in hair follicle stem cells promotes their proliferation, self-renewal, and differentiation while inhibiting apoptosis through the FGF2-mediated PI3K/AKT signaling pathway, suggesting potential therapeutic applications for hair loss treatment.

This study reported that high-dose mizoribin therapy may be effective and safe for managing steroid-dependent pediatric systemic lupus erythematosus but requires monitoring of serum uric acid levels due to potential side effects.

This study found that fractional radiofrequency microneedling may be as effective and safe as intralesional corticosteroid injections for treating patchy alopecia areata, with potentially fewer side effects.

This commentary piece identifies interleukin-13 as a potential therapeutic target for treating alopecia areata associated with atopic dermatitis, although specific study results or outcomes are not provided in the abstract.

This review examines emerging and past therapies for recurrent implantation failure, focusing on three innovative strategies: PBMC, G-CSF, and PRP, but reports no new clinical results.

This study suggests a potential role for S100A7 and IL-17 in the pathogenesis of lichen planopilaris.

This study reports that anifrolumab showed promising improvement in a case of refractory discoid lupus erythematosus, specifically enhancing skin lesions and promoting hair regrowth, suggesting potential as an effective therapy for severe cases.

This study identified that certain genetic polymorphisms in IL-16 are associated with an increased risk of alopecia areata in an Iraqi population.